Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. has announced that its lead drug formulation, Rutherrin®, has shown promise in preclinical research for boosting chemotherapy efficacy and overcoming multidrug resistance in cancer treatments. The drug works by potentially inhibiting the function of drug-efflux pumps in cancer cells, leading to higher retention and effectiveness of various chemotherapeutic agents. This breakthrough could enhance the therapeutic response in cancer patients and address the challenge of treatment resistance.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
